MedTrace Logo

Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)

NCT07538791 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2026-04-24

No results posted yet for this study

Summary

This multicenter retrospective Italian study evaluates the efficacy and safety of PRRT in patients with advanced, unresectable or metastatic pheochromocytomas and paragangliomas (PPGL). Data from \~210 patients treated between 2000 and 2024 will be analyzed. The primary endpoint is disease control rate (DCR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), and prognostic factors.

Conditions

  • Pheochromocytomas
  • Paragangliomas

Interventions

RADIATION

Peptide Receptor Radionuclide Therapy (PRRT)

PRRT with radiolabeled somatostatin analogues (¹⁷⁷Lu and/or ⁹⁰Y), according to clinical practice.

Sponsors & Collaborators

  • Azienda USL Reggio Emilia - IRCCS

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2026-04-30
Completion
2028-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07538791 on ClinicalTrials.gov